



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of

von BORSTEL et al

Atty. Ref.: 1331-352

Serial No. 09/930,494

TC/A.U.: 1623

Filed: August 16, 2001

Examiner: Patrick T. Lewis

For: COMPOSITIONS AND METHODS FOR TREATMENT OF  
MITOCHONDRIAL DISEASES

\* \* \* \* \*

January 26, 2006

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT**


As suggested by 37 C.F.R. 1.97, the undersigned attorney brings to the attention of the Patent and Trademark Office the references listed on the attached form PTO-1449. The requisite IDS fee is attached.

The Examiner is requested to initial the attached form PTO/SB/08a and to return a copy of the initialed document to the undersigned.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_

  
Leonard C. Mitchard  
Reg. No. 29,009

LCM:lfm  
901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

01/27/2006 SZEWDIE1 00000082 09930494

02 FC:1806

180.00 0P

1037058


**INFORMATION DISCLOSURE  
CITATION**

ATTY. DOCKET NO.

1331-352

SERIAL NO.

09/930,494

APPLICANT

von BORSTEL et al

(Use several sheets if necessary)

FILING DATE

August 16, 2001

TC/A.U.

1623

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

	Saydoff <i>et al.</i> "Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease", <i>Brain Res.</i> (2003) 994(1):44-54
	Gines <i>et al.</i> , "Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice", <i>Hum Mol Genet.</i> (2003);12(5):497-508 (Abstract)
	Lam et al (Eur J Pediatr. 1997 Jul;156(7):562-4. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. Lam CW, Lau CH, Williams JC, Chan YW, Wong LJ. Department of Pathology, Princess Margaret Hospital, Lai Chi Kok, Hong Kong)
	Krahenbuhl et al (Liver. 2000 Jul;20(4):346-8; Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Krahenbuhl S, Brandner S, Kleinle S, Liechti S, Straumann D. Department of Clinical Pharmacology, University of Berne, Switzerland)
	Ritchie et al., "Diagnostic Approach to Polyarticular Joint Pain", <i>American Family Physician</i> , 68, 6, 1151-1160 (2003)
	Page, et al., "A Syndrome of Megaloblastic Anemia, Immunodeficiency, and Excessive Nucleotide Degradation," in Purine and Pyrimidine Metabolism in Man VII, Part B, Harkness, et al. eds (1991) pp. 345-348
	DiMauro, et al, "Mitochondrial encephalomyopathies: where next?", <i>Revista de Neurologia</i> (1999) 28(2):164-168
	Luft, "Review: The development of mitochondrial medicine", <i>Proc. Natl. Acad. Sci. USA</i> (September 1994) 91: 8731-8738
	Beal, "Mitochondrial dysfunction in neurodegenerative diseases", <i>Biochimica et Biophysica Acta</i> (1998) 1366: 211-223
	Blass, "Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia", <i>J. Neurosc. Res.</i> (2001) 66: 851-856
	Bowling, et al., "Minireview: Bioenergetic and Oxidative stress in neurodegenerative diseases", <i>Life Sciences</i> (1995) 56(14): 1151-1171
	Beal, "Mitochondria, free radicals, and neurodegeneration", <i>Current Opinion Neurobiol.</i> (1996) 6: 661-666
	Browne, et al, "Oxidative damage and mitochondrial dysfunction in neurodegenerative diseases", <i>Biochem. Soc. Trans.</i> (1994) 22: 1002-1006
	Schulz, et al., "Mitochondrial dysfunction in movement disorders", <i>Current Opinion in Neurology</i> (1994) 7:333-339

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Sheet 2 of 1

INFORMATION DISCLOSURE  
CITATION

ATTY. DOCKET NO.

1331-352

APPLICANT

von BORSTEL et al

FILING DATE

August 16, 2001


SERIAL NO.

09/930,494

TC/A.U.

1623

(Use several sheets if necessary)



\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.